abrdn Life Sciences Investors

Veradermics Completes $256M IPO and Advances Non-Hormonal Hair Loss Treatment

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

VeraDermics released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -36.3209 (forecast USD -0.705)

VeraDermics released FY2025 Q1 earnings on May 12, 2026 (EST), actual revenue USD 0, actual EPS USD 0

Veradermics Details Late-Stage Plans for VDPHL01

Veradermics Reports Increased Net Loss in Q1 2026

Dyne Therapeutics released FY2026 Q1 earnings on May 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7322 (forecast USD -0.7716)

Argenx SE Receives FDA Approval to Expand Indications for MG Drugs

Barclays Maintains Buy Rating on arGEN X with a Price Target of 900 Euros

Jefferies Analyst Reiterates Buy Rating on arGEN X

Denali Therap released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 2.322 M), actual EPS USD -0.6882 (forecast USD -0.7155)

Crinetics Pharmaceuticals released FY2026 Q1 earnings on May 7 After-Market EST, actual revenue USD 10.73 M (forecast USD 8.615 M), actual EPS USD -1.23 (forecast USD -1.2227)

FactSet: Insmed Inc 2026 EPS forecast median revised down to -2.5 USD

Argenx released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 1.313 B (forecast USD 1.284 B), actual EPS USD 5.5199 (forecast USD 5.0946)

Edgewise Therapeutics released FY2026 Q1 earnings on May 7 Pre-Market EST, actual EPS USD -0.4599 (forecast USD -0.4855)

Insmed released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 305.96 M (forecast USD 300.8 M), actual EPS USD -0.76 (forecast USD -0.9804)

Aliram Pharmaceuticals to Participate and Live-stream Two Healthcare Conferences

argenx Releases 2026 First Quarter Financial Results and Provides Business Update

Vaxcyte released FY2026 Q1 earnings on May 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.2982 (forecast USD -1.8057)

Insmed CEO William Lewis Sells 10,699 Shares of Company Stock

OPTIMI HEALTH CORP

Silexion Therapeutics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

GCL Global

HCW Biologics

Jupiter Neurosciences

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Ordinary dividend (cash)

Ex Date: 2026.05.21 (EST), Cash dividend 0.56 USD

Shares of abrdn Life Sciences Investors (NYSE:HQL) reached a new 52-week high of $18.10, closing at $18.1250 with a trading volume of 68,327 shares. The stock has seen a 1.7% increase and has a 50-day moving average of $16.88. The company recently raised its quarterly dividend to $0.56 per share, yielding 12.3%. Institutional investors have increased their stakes, with 32.21% of the stock owned by such entities. The company focuses on investments in the life sciences sector, including biotechnology and pharmaceuticals.

Market Beat

abrdn Healthcare Investors

abrdn Life Sciences Investors (NYSE:HQL) Hits New 52-Week High  - Time to Buy?

abrdn Life Sciences Investors (NYSE:HQL) reached a new 52-week high of $18.10, closing at $18.00 with a trading volume of 134,715 shares. The company recently increased its quarterly dividend from $0.50 to $0.56, yielding 12.5%. Institutional investors have significantly increased their stakes, with Shaker Financial Services growing its position by 536.8%. abrdn Life Sciences Investors focuses on capital appreciation in the life sciences sector, investing in biotechnology, pharmaceuticals, and healthcare technology.

LPL Financial

abrdn Life Sciences Investors (NYSE:HQL) Sets New 1-Year High  - Here's Why

NDIA

ASGI

Aberdeen Investments U.S. Closed-End Funds announced distribution payments on March 31, 2026, for shareholders of record as of March 24, 2026. The funds include ASGI, HQH, HQL, IAF, IFN, and THQ, with varying distribution amounts per share. Certain funds automatically paid distributions in newly issued shares unless cash was requested. The estimated sources of distributions include net investment income, realized gains, and return of capital, with specific percentages outlined for each fund. Shareholders had to notify their brokers by March 17, 2026, to receive cash instead of shares.

MorningStar

abrdn World Healthcare

abrdn Global Dynamic Dividend Fund

abrdn Healthcare Opportunities

Global X India Active ETF

abrdn Australia Equity Fund

abrdn Global Infrastructure Income Fund

India Fd

Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details

INDA

Aberdeen Investments U.S. Closed-End Funds have announced distribution dates and amounts for various funds. Distributions will be paid on February 27, 2026, to shareholders of record as of February 20, 2026, with an ex-dividend date of February 20, 2026. Notably, the abrdn Healthcare Investors, abrdn Life Sciences Investors, abrdn Australia Equity Fund, and the India Fund will pay distributions on March 31, 2026. Shareholders can opt for cash or stock distributions, with specific instructions provided for each option.

prnewswire

ISHRS MSCI India

16:17 ETCertain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts

abrdn Life Sciences Investors(HQL.US)

abrdn Life Sciences Investors (NYSE:HQL) Hits New 52-Week High - Time to Buy?

abrdn Life Sciences Investors (NYSE:HQL) Sets New 1-Year High - Here's Why

Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details

16:17 ETCertain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts